

1 Associations Between Blood Markers of the GSH Redox cycle and 2 Brain White Matter Microstructure in Psychosis

3 Tommaso Pavan¹, Pascal Steullet², Yasser Alemán-Gómez¹, Raoul Jenni², Zoé Schilliger^{2,6},
4 Martine Cleusix², Luis Alameda^{3,4,5}, Kim Q. Do², Philippe Conus³, Patric Hagmann¹, Daniella
5 Dwir², Paul Klauser^{2,6}, and Ileana Jelescu¹

6 1. Department of Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne,
7 Switzerland

8 2. Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital and the
9 University of Lausanne, Lausanne, Switzerland

10 3. Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program. Lausanne University
11 Hospital (CHUV), Lausanne, Switzerland

12 4. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience. King's College of
13 London, London, UK.

14 5. Centro Investigacion Biomedica en Red de Salud Mental (CIBERSAM); Instituto de Biomedicina de Sevilla (IBIS),
15 Hospital Universitario Virgen del Rocio, Departamento de Psiquiatria, Universidad de Sevilla, Sevilla, Spain.

16 6. Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital and the
17 University of Lausanne, Lausanne, Switzerland

18 Corresponding author: Tommaso Pavan; address: *Centre de Recherche en Radiologie*, PET3, CHUV, Rue du Bugnon 46,
19 1011, Lausanne, Switzerland ; telephone:+41213146020; fax:+41213146020; email: tommaso.pavan@chuv.ch

20

21

22

23

24

25 Abstract

26 In groups of patients suffering from psychosis, redox dysregulation was reported in both peripheral fluids and brain.
27 It has been hypothesized that such dysregulation, including alterations of the glutathione (GSH) cycle could
28 participate in the brain white matter (WM) abnormalities in schizophrenia (SZ) due to the oligodendrocytes'
29 susceptibility to oxidative stress (OxS).

30 In this study we aim to assess the differences between 99 psychosis patients (PT) and 86 healthy controls (HC) in
31 GSH-redox peripheral blood markers: GSH peroxidase (GPx), reductase (GR) enzymatic activities and their ratio
32 (GPx/GR-ratio), evaluating the hypotheses that alterations in the homeostasis of the systemic GSH cycle may be
33 associated with pathological mechanisms in the brain WM in PT. We also consider the hypothesis that different
34 homeostatic states of the system (oxidative vs reductive) may reflect differently into the WM microstructure. To do
35 so, we employ the advanced diffusion MRI methods: Diffusion Kurtosis Imaging (DKI) and White Matter Tract
36 Integrity-Watson (WMTI-W), which provide excellent sensitivity to demyelination and neuroinflammation.

37 We show that GPx levels are higher ($p=0.00050$) in female participants and modulate the effect of aging on the WM.
38 We found differences between PT and HC in the association of GR and mean kurtosis (MK, $p=0.028$). Namely, lower
39 MK was associated with higher blood GR activity in HC, but not in PT, suggesting that high GR activity (a hallmark of
40 reductive stress) in HC was linked to changes in myelin integrity. Remarkably, GSH-redox peripheral blood markers
41 did not explain the WM anomalies detected in PT.
42

43 Introduction

44 Psychosis and schizophrenia (SZ) present significant challenges for patients, their families, and society¹. Only
45 partially understood, its etiology is attributed to a multifaceted interplay of genetic, environmental and
46 developmental factors that affect a variety of biological processes²⁻⁷ among which the redox balance⁸. In patients
47 suffering from psychosis, a redox dysregulation is reported in peripheral fluids (i.e., diminished antioxidant capacity,
48 oxidative damage of lipids, DNA and RNA⁹⁻¹¹) and brain (i.e., lower glutathione (GSH), lower NAD⁺/NADH ratio^{12,13}).
49 The causes of such redox dysregulation and the resulting oxidative stress (OxS) are multifactorial, including
50 compromised energy metabolism, endocrine dysregulation, chronic subclinical inflammation and weakened
51 antioxidant capacities. Anomalies in the GSH redox system, a key antioxidant system for cell protection and
52 detoxification, have been widely observed in SZ⁹. While polymorphisms in genes of the GSH system have been
53 associated with SZ¹⁴⁻¹⁹, meta-analyses also show lower mean levels of GSH in blood⁹, and brain^{13,20-22} in patients vs.
54 controls. The redox regulation and antioxidant function of GSH acts largely via the GSH redox cycle that involves the
55 GSH peroxidase (GPx) and GSH reductase (GR). GPx neutralizes peroxides by oxidizing GSH into GSH-disulfide
56 (GSSG). In turn, GR reduces GSSG back to GSH. Thus, GPx and GR activities and the GPx/GR ratio inform about the
57 homeostasis of this system. Two out of three postmortem studies have found lower brain GPx in patients vs.
58 controls²⁰⁻²². Meta-analyses suggest that SZ patients tend to display also lower blood GPx than controls⁹. The
59 decrease in peripheral GPx activity seems, however, mostly found in chronic patients²³, with variable levels among
60 early psychosis (EP) patients. Thus, EP patients with worse psychosocial outcomes after a 3-year clinical follow-up
61 displayed significantly higher GPx activity at baseline than those with better outcome²⁴. By contrast, there is no
62 evidence of consistent alterations of GR in brain²⁰ and blood⁹.

63 It has been hypothesized that a GSH deficit could participate to the brain white matter (WM) abnormalities in SZ^{25,26},
64 consequential to the oligodendrocytes susceptibility to OxS²⁷, due to their elevated metabolic activity and high iron
65 content for the production and maintenance of the myelin sheaths^{28,29}. The GSH redox cycle is involved in the
66 integrity of WM, from the survival, proliferation and differentiation of the oligodendrocyte precursor cells^{26,30} (OPC),
67 to the protection of oligodendrocytes against OxS thanks to high GPx expression^{31,32}. A dysregulation of the GSH
68 system will also alter axons' energy metabolism³³ and mitochondrial activity³⁴. Furthermore, this dysregulation can
69 lead to subclinical activation of microglia³⁵, which may in turn affect WM, due to its role in the WM myelin remodeling
70 via OPC recruitment and phagocytosis of myelin debris, de-myelination and remyelination³⁶. *Post-mortem* studies on
71 SZ patients have described diminished oligodendrocyte densities in cortical layer III and subcortical areas, presence
72 of swollen or dystrophic oligodendroglia³⁷⁻³⁹, adjacent microglia⁴⁰, decompacting and splitting of the myelin sheath
73 with inclusions of vacuoles between myelin layers³⁷⁻³⁹.

74 Abnormal WM integrity in EP is also widely reported using *in-vivo* diffusion magnetic resonance imaging (dMRI).
75 DMRI leverages the random motion of water molecules to infer the microstructural properties of the underlying
76 biological tissue⁴¹. Most studies investigating the psychosis spectrum show widespread increased mean diffusivity
77 (MD) and/or reduced fractional anisotropy (FA)⁴²⁻⁴⁷ with medium effect sizes⁴⁶ (*Cohen's d*=0.42), consistent with
78 anomalies described in the *post-mortem* studies. However, the evidence of a link between WM anomalies and the

79 GSH system in subjects with psychosis remains sparse. GSH levels in frontal brain regions have been found to
80 correlate positively with generalized FA (gFA) in the cingulum of both EP patients and controls²⁶, while it was shown
81 in earlier work that the precursor of GSH and antioxidant, N-acetylcysteine (NAC), improves the integrity of the
82 fornix (i.e., increases gFA) in EP patients⁴⁸ and increases brain GSH⁴⁹.

83 Here, we aim to assess in patients with psychosis whether the activity of GPx, GR, and the GPx/GR ratio measured in
84 blood cells (which inform about the systemic homeostasis of the GSH redox cycle) are associated with the WM
85 microstructure estimated using dMRI. For this purpose, we utilized advanced dMRI methods: Diffusion Kurtosis
86 Imaging^{50,51} (DKI), an extension of the diffusion tensor imaging (DTI), and the biophysical model White Matter Tract
87 Integrity-Watson^{52,53} (WMTI-W). In addition to classical DTI measures such as MD and FA, DKI enables the estimation
88 of the mean kurtosis (MK), a measure of diffusion variance within each voxel arising from heterogeneous sub-
89 domains, such as cellular compartments, which provides complementary information about tissue heterogeneity.
90 The WMTI-W model allows the estimation of specific microstructural cellular features such as the axonal density (f)
91 in each voxel, with less *ad hoc* simplifying assumptions, less fit constraints^{54,55} and increased validity⁵⁵ as compared
92 to other biophysical methods such as free-water imaging⁵⁶ (FWI) and Neurite Orientation Dispersion and Density
93 Imaging⁵⁴ (NODDI). We focused our analysis on these four metrics (MD, FA, MK, f) because of their ability at detecting
94 abnormal myelination or demyelination⁵⁷⁻⁶⁰ (\uparrow MD, \downarrow FA, \downarrow MK, $\downarrow f$), but also neuroinflammation which has the effect
95 of reducing diffusivities (\downarrow MD, \downarrow FA) and increasing kurtosis and apparent axonal water fraction (\uparrow MK, $\uparrow f$) due to
96 higher cellular crowding associated with microgliosis and astrocytosis^{57,58,61,62}. In a recent study, we have shown an
97 increase in MD and a decrease in FA, MK and f in the WM of patients with psychosis when compared to age range-
98 matched controls, with these alterations being surprisingly more pronounced during the first years of psychosis⁶³.

99 Here we hypothesize that alterations in the homeostasis of the systemic GSH redox cycle may be associated with
100 pathological mechanisms in the brain (i.e., redox dysregulation and microglia dysfunction) that affect WM. Therefore,
101 we expected that peripheral markers related to the GSH redox cycle may correlate with some of the WM
102 microstructure metrics, sensitive to neuroinflammation and myelination, as previous treatment studies targeting the
103 GSH redox system via NAC have shown an increase in brain GSH⁴⁹ and improvement of gFA in the fornix⁴⁸. We also
104 anticipate that relationships between the GSH redox cycle and WM differ in healthy controls (HC) and patients, but
105 also between subgroups of participants classified as having low GPx/GR-ratio versus high GPx/GR-ratio.

106

107 **Methods**

108 **Participants**

109 Data were collected from 185 individuals (**Table 1**) divided into two groups: 86 healthy controls (HC), 99 patients
110 (PT) with a diagnosis from the psychosis spectrum (**Supplementary Table S1**). Patients that suffered at least one
111 psychotic episode (as defined by Comprehensive Assessment of At-Risk Mental States scale⁶⁴, CAARMS) or had DSM-
112 IV diagnosis of SZ and schizoaffective disorder were recruited from the Lausanne University Hospital. PT with
113 psychosis related to intoxication or organic brain disease, IQ<70, reporting alcoholism, drug abuse, major somatic
114 disease, documented anamnestic or current organic brain damage were excluded. HC were recruited from the same
115 sociodemographic area as the patients. HC were excluded if they had a first-degree family member who suffered from
116 psychosis or prodromal symptoms, or if they reported current or past antipsychotic treatments. Symptoms in PT
117 were assessed via the Positive and Negative Syndrome Scale⁶⁵ (PANSS), and global functioning was estimated for the
118 whole sample via the Global Assessment of Function⁶⁶ scale (GAF). The study was approved by the local Ethics
119 Committee of the Canton of Vaud (Switzerland) under authorization numbers CER-VD 382/11 and 2018-01731.

120

121 **MRI acquisition**

122 MRI scanning sessions were performed on two different 3-Tesla systems (Magnetom TrioTim and PRISMA, Siemens
123 Healthineers, Erlangen, Germany), each equipped with a 32-channel head coil. A 1-mm isotropic T1-weighted image
124 was acquired for anatomical reference. Whole-brain diffusion-weighted images (DWI) were acquired using diffusion
125 spectrum imaging (DSI) scheme across 15 b-values, ranging from 0 to 8000 s/mm², spatial resolution of 2.2 x 2.2 x 3
126 mm³ - See Supplementary Material for further acquisition details.

127 **Image preprocessing**

128 The MPRAGE image was bias field corrected⁶⁷ and skull-stripped via nonlinear registration to the MNI-152 template⁶⁸
129 using Advanced Normalization Tools⁶⁹ (ANTs). The diffusion preprocessing pipeline included MP-PCA denoising,
130 Gibbs ringing-, EPI-, eddy current and motion corrections, following most recent guidelines⁷⁰ - see Supplementary
131 Material for preprocessing details.

132
133

Microstructure estimation

134 For DKI and WMTI-W estimation, the diffusion dataset was truncated⁵⁰ at $b \leq 2500$ s/mm². DKI was fit voxel-wise in
135 the entire brain⁷¹ using a weighted linear-least squares algorithm in Matlab⁷¹, from which seven scalar maps were
136 derived. Four from DTI: RD, MD, AD and FA, and three from DKI: radial, mean, axial kurtosis (RK, MK, AK). However,
137 only three parameter maps were included in the statistical analysis: MD, FA, and MK. WMTI-W parameters were
138 estimated voxel-wise from the seven DKI scalars, using an in-house Python script, yielding five parameter maps:
139 axonal density f , intra-axonal diffusivity D_a , extra-axonal parallel and perpendicular diffusivities $D_{e,||}$, $D_{e,\perp}$ and axon
140 orientation alignment c_2 . However, only axonal density f was included in the statistical analyses, to limit the number
141 of comparisons.

142
143

Blood analyses

144 GR and GPx activity were assessed in hemolyzed blood cells incubated in phosphate buffer solution (100mM, pH 7.5)
145 containing EDTA (0.6mM), and non-limiting levels of either oxidized glutathione (GSSG, 2.5mM) and NADPH
146 (0.25mM) (for GR), or GSH (2.5mM), NADPH (0.25mM), GR (0.84U/ml; Fluka) and tert-butyl hydroperoxide (TBHP,
147 0.8mM, Fluka) (for GPx). We expressed GPx and GR activities in nmoles NADPH used/min/g hemoglobin. These
148 enzymatic activities were measured with two different plate readers. Batch effects between plate readers were
149 corrected via Combat for biological data⁷² (see additional details on the blood analyses and harmonization procedure
150 in the supplementary material).

Statistical analysis

Blood markers analysis

153 Statistical analyses were run in R⁷³, group comparisons were computed via Welch's t-test and ANOVA. Robust linear
154 regression⁷⁴ was used for all the regression and contrasts analyses, always including a correction by (quadratic) age,
155 sex. Post-hoc pairwise contrasts were multiple comparisons corrected via False-Discovery Rate (FDR).

156 Evidence about the influence of aging on the redox system has been reported in the literature^{75,76}, suggesting the
157 system is maintained until ~ 45 years of age⁷⁶. We evaluated this hypothesis first by considering age as a continuous
158 variable and then by comparing subjects under and above 40 years old ($N_{<40y.o.}=165$, $N_{\geq 40y.o.}=21$).

Association between blood markers and WM microstructures

160 Before any statistical analysis, all the microstructure parameter estimates were harmonized for scanner type via
161 ComBat harmonization⁷⁷, which was proven efficient at correcting scanner effects in the same cohort⁷⁸. Furthermore,
162 participants with a delay between MRI scan and blood samples larger than 60 days were excluded whenever an
163 association between blood biomarkers and WM microstructure metrics was tested (84% of the original cohort,
164 $N_{HC}=80$, $N_{PT}=76$, $\text{delay}_{HC}=10.0 \pm 11.7$, $\text{delay}_{PT}=19.0 \pm 16.0$, $p < 0.0001$). All analyses included a correction for (quadratic)
165 age, sex, and delay. Associations were initially tested at a whole WM level and then at voxel level using FSL's Tract-
166 Based Spatial Statistics⁷⁹ (TBSS). First, individual FA maps were used to build a study-specific FA template using
167 ANTs⁶⁹ and the estimated warps were used to spatially normalize each individual FA, MD, MK and f map. From the
168 average FA, a WM skeleton was estimated and warped-back to native space where individual FA, MD, MK, and f
169 averages were computed for the whole WM skeleton analysis. While, at voxel level, the skeleton voxels were
170 harmonized in template space with ComBat⁷⁷ before permutation testing (FSL randomise⁸⁰, 5000 permutations).
171 The resulting statistical maps were FDR and Threshold-Free Cluster Enhancement (TFCE) corrected.

Low and High GPx/GR ratio analysis

173 To study if there could be differences between participants showing different levels of GPx and GR activity, we
174 repeated the analysis described above after re-classifying the participants into two groups according to their
175 GPx/GR-ratio. Low-ratio and high-ratio were defined as having a GPx/GR-ratio respectively lower and higher than
176 the median GPx/GR ratio of the HC group (**Fig.1A**, Median_{HC}=6.64).

177

Results

Demographics

180 Summary demographics of the cohort can be found in **Table 1**. PT (29 \pm 9 y/o) and HC (28 \pm 8 y/o) did not differ in age
181 ($p=0.39$). Differences were found between PT and HC in functional levels as measured by the GAF scale ($p < 0.0001$)

182 and in the delay between MRI acquisition and blood collection ($p < 0.0001$), leading to the inclusion of this variable as
183 covariate.

184 **GSH-redox cycle system**

185 Overall, GPx ($p = 0.60$) and GR ($p = 0.19$) activities or the GPx/GR-ratio ($p = 0.39$) did not differ between PT and HC
186 groups. When pooling together HC and PT, female participants showed higher GPx activity than males ($p = 0.00050$).
187 GPx and GR activities correlated significantly for the whole cohort ($r = 0.38$, $p < 0.0001$, **Fig. 1A**), but also for PT ($r = 0.35$,
188 $p < 0.0001$) and HC ($r = 0.40$, $p = 0.00013$) when considered independently. The slope contrast between PT and HC did
189 not show any significant difference ($p = 0.72$, **Fig. 1B**). GPx and GR activities correlated also in both males and females
190 (respectively, $r = 0.47$, $p = 0.00024$ and $r = 0.37$, $p = 0.00037$) with no significant sex difference for the slopes either
191 ($p = 0.15$, **Fig. 1C**). Age was only found significantly associated with a decrease in GPx activity ($p = 0.026$). This decrease
192 was particularly significant in participants over 40 years old. This group displayed lower GPx levels ($p = 0.00083$) and
193 ratio ($p < 0.0001$, but not GR, $p = 0.89$) when compared to under 40 years old. Finally, GPx activity and GPx/GR-ratio
194 were found negatively associated with the duration of illness in PT ($p < 0.0001$) but not with age at psychosis onset or
195 medication.

196

197 **Associations between GSH-redox cycle and WM microstructure**

198 Within the whole cohort, irrespective of the clinical status or sex, neither GPx, GR, or their ratio correlated with
199 average WM skeleton values of MD, FA, MK, or f . When considering the clinical status, GR regression models with MK
200 ($p = 0.028$, **Fig. 2A**) and f ($p = 0.043$, **Fig. 2B**) showed significant differences between HC and PT slopes. The GPx/GR-
201 ratio association with f also showed a difference between HC and PT slopes ($p = 0.027$, **Fig. 2C**), while a trend could
202 be observed for MK ($p = 0.054$). No significant differences between HC and PT were found for GPx association with
203 either MD, FA, MK or f .

204 TBSS analysis of the same regressions further substantiates the relationships of GR with MK but not the associations
205 of f with GR or the GPx/GR-ratio. In HC, MK was significantly and negatively associated with GR in multiple WM
206 clusters (**Fig. 2D**). Furthermore, the slope (GR-MK) in HC differed significantly from the one in PT (**Fig. 2E**). The
207 significant contrast was localized bilaterally in the superior corona radiata (CR), genu and body of the corpus
208 callosum (CC).

209

210 **Associations between GPx, age, sex and WM microstructure**

211 In light of the negative association between GPx levels and age, we also evaluated whether their interaction could be
212 reflected in the WM microstructure. Irrespectively of the clinical status, the interaction model of GPx and quadratic
213 age, corrected for sex and delay, resulted in a significant interaction for MD ($p = 0.0017$, **Fig. 3**). Namely, with aging,
214 MD was overall higher in individuals with low GPx activity than in individuals with elevated GPx activity, irrespective
215 of the clinical status. We also considered the 3-way interaction of GPx, aging, and clinical status on the association
216 with MD, but we did not find any significant interaction ($p = 0.18$). Complementary TBSS analysis did not show any
217 significant cluster for the same regressions.

218

219 **Low GPx/GR-ratio versus high GPx/GR-ratio**

220 We expected individuals with high GPx/GR-ratio to have a more oxidized redox state of the GSH/GSSG couple than
221 those with a low GPx/GR-ratio. The highest GPx/GR-ratios may indicate systemic OxS, while the lowest GPx/GR-ratios
222 may reflect the presence of reductive stress.

223 PT were distributed equally between the low-ratio and a high-ratio group (**Table 1**), indicating no overall differences
224 between PT and HC. First, we established that the low- vs high-ratio is driven by both GPx and GR levels. Considering
225 both PT and HC together, participants with low ratio ($p < 0.0001$) had significantly lower GPx ($\mu_{GPx} = 13.09$) and higher
226 GR ($\mu_{GR} = 2.61$) as compared to subjects with high ratio ($\mu_{GPx} = 19.76$, $\mu_{GR} = 2.16$). The same pattern was observed within
227 the clinical groups and sex ($p < 0.0001$). GPx and GR significantly correlated within both low- ($r = 0.65$, $p < 0.0001$) and
228 high-ratio ($r = 0.74$, $p < 0.0001$) groups, but their slopes significantly differed ($p = 0.036$) suggesting a tighter
229 coordination of GPx and GR in the high-ratio group. Pairwise contrasts between the slopes of the interaction models
230 of low- and high- ratio with the clinical status (6 tests) did not yield significant results.

231

232 **Associations between GSH-redox cycle and dMRI WM microstructure in the low and high GPx/GR-ratio** 233 **groups**

234 We then assessed how low and high GPx/GR-ratio reflected at the WM microstructure level. Overall, the WM metrics
235 did not significantly differ between individuals with low and high ratio after correcting for quadratic age, sex and
236 delay. Two-way interaction models of low- and high- ratio with either sex or clinical status did not yield significant
237 differences. However, the 3-way interaction model of MK (low- and high- ratio, sex and clinical status) showed a
238 significant interaction in GPx ($p=0.012$) and a trend for GR ($p=0.080$). *Post-hoc* comparisons (4 tests: low- vs high-
239 ratio, and PT vs HC) of the two MK models found significant differences in the slopes of GPx ($p_{\text{FDR}}=0.038$, **Fig. 4A**) and
240 GR ($p_{\text{FDR}}=0.016$, **Fig. 4B**) in low-ratio HC vs low-ratio PT.

241 TBSS voxel-wise analysis of the same 3-way interaction model showed widespread significant differences in the
242 slopes of MK vs GR between low ratio HC and PT (**Fig. 4C**) but not for any other comparison, indicating the low-ratio
243 group drives the difference between HC and PT. Identified areas for the GR-MK association were the bilateral
244 cerebellar peduncle (CP), internal capsule, the splenium and body of the CC, the whole CR, the right superior
245 longitudinal fasciculus (SLF), right tapetum, genu of the CC, thalamic radiation, fronto-occipital fasciculus (FOF),
246 and the fornix. Notably, many voxels of the peripheral WM were also significant.

247

248 **Discussion**

249 In this work, we quantified peripheral biomarkers of the GSH redox cycle (GPx, GR activities and their ratio) in
250 patients with psychosis and control subjects, and we explored the relationships of these redox markers with the WM
251 microstructure estimated with advanced dMRI methods. We did not find significant differences in GPx, GR or GPx/GR-
252 ratio between groups. However, female participants showed higher GPx activity than males, independently of their
253 clinical status. GPx was also the only biomarker whose activity decreased with age. Regarding the WM metrics (MD,
254 FA, MK, f), only MD changed significantly with aging, with the older subjects displaying in higher MD at lower GPx.
255 Finally, GR activity was negatively associated with MK in HC, but not in PT, mostly driven by the subgroup of
256 individuals with a low GPx/GR-ratio where the differences between HC and PT was considerably enhanced and more
257 widespread across the WM.

258

259 *Peripheral GSH redox cycle*

260

261 Many studies have investigated blood GPx and GR activities in cohorts of psychotic patients^{9,22,23,81}, sometimes with
262 mixed results. However, meta-analyses^{9,23} show overall significantly lower GPx, but not GR, in PT as compared to HC.
263 To our knowledge, the GPx/GR-ratio has not yet been examined. The analysis of Flatow et al.²³ indicates that a
264 decrease in GPx activity was prevalent in patients with chronic SZ or in PT with acute relapse but not with first
265 psychosis episode. In our cohort, which includes PT with early psychosis or chronic SZ, we did not find any difference
266 between PT and HC regarding GPx, GR and their ratio, even after correction for age and sex. However, we observed
267 higher GPx activity in females than males and decreased GPx activity with aging (particularly above 40 years old),
268 independently of the clinical status. Thus, some of the discrepancies among studies on PT with psychosis could be
269 explained, not only by the stage of the disease, but also by overlooked effects on the peripheral markers of aging^{76,82,83},
270 sex⁸⁴, medication⁸⁵ and circadian rhythm (see ⁸ supplementary), methodological differences in sample collection,
271 processing, storage, and quantification. However, our findings of sex and age effects on blood GPx activity, regardless
272 of the clinical status, corroborate results from numerous studies^{76,82-84,86}. Higher levels of GPx, but not GR, have been
273 also widely reported in the brain of females as compared to males in both animals and humans⁸⁷⁻⁸⁹. A higher GPx
274 activity in females is consistent with more efficient antioxidant systems and less basal inflammation in females than
275 in males⁸⁷. Our observation of a diminished GPx activity with age is also in line with the literature⁷⁵ and with the
276 notion that the antioxidant defenses weaken over the years, contributing to the accumulation of OxS and its harmful
277 effects⁸³. In our work, we found that GPx and GR activities correlated positively within both PT and HC and within
278 both males and females, suggesting a generally quite well-coordinated GSH redox cycle. Of note, the activity of both
279 enzymes correlated in female, adolescents only from the general population⁸⁴, but not in EP patients who had been
280 exposed to childhood trauma⁹⁰. This suggests that the relationship between GPx and GR activities may differ in a sex-
281 dependent manner during adolescence but also among subgroups of individuals according to environmental and
282 other yet unidentified factors. Elevated GPx/GR-ratio and/or GPx activity in blood cells may reflect a condition of
283 systemic OxS, while low GPx/GR-ratio and/or high GR activity may indicate systemic reductive stress. Of note, PT
284 who benefited from a NAC treatment were mostly those with high blood GPx activity⁴⁸. On the other hand, reductive
285 stress is the result of a shift of the redox balance in biological redox couples (i.e., GSSG/GSH, or NAD⁺/NADPH) to a
286 more reducing state. This reductive stress can disturb redox-sensitive biological processes, but also lead

287 paradoxically to increase mitochondrial reactive oxygen species (ROS) production, thus overwhelming the ROS
288 neutralization capacity and causing mitochondrial dysfunction and oxidative damage⁹¹. Of note, PT with SZ younger
289 than 40 years-old were reported to display signatures of reductive stress as compared to age-matched HC¹².

291 *Associations between peripheral GSH redox cycle and WM microstructure*

292
293 Due to the diversity in the GSH redox cycle status across individuals and the complex effects of sex and age, it was
294 therefore essential to tackle the relationships between the peripheral redox markers and WM microstructure by
295 carefully considering age, sex and their interactions, and by investigating the links between the GSH redox cycle and
296 WM separately in subgroups of individuals characterized by different peripheral redox profiles.

297 Thus, we first found that MD (the average diffusion coefficient in the tissue) was predicted by the interaction between
298 GPx and aging. MD has been shown to increase in WM with normal aging⁹², due to the reduced numbers of myelinated
299 axons, inefficient remyelination processes, increased number oligodendrocytes and excessive myelination around
300 some axons⁹³.

301 Our results suggest that GPx may modulate the effect of aging on the WM microstructure as reflected by MD. We found
302 that individuals with low GPx activity tended to display higher MD than subjects with high GPx activity with aging,
303 independently from the clinical status (**Fig. 3**). This is consistent with the antioxidant effect of GPx and with the idea
304 that OxS may contribute to accelerated aging in SZ⁹⁴. We believe the reason for the lack of differences between PT
305 and HC in this association is the sparsity of subjects above 40 years old ($N_{>40y.o.}=21$) which makes the modelling at
306 older ages challenging.

307 The strongest differences between PT and HC were found in the association of GR with the WM microstructure (**Fig.**
308 **2, 4**), particularly with MK. MK is considered a measure of tissue complexity^{50,51}, which has demonstrated sensitivity
309 at detecting abnormal myelination⁵⁷⁻⁶⁰, neurodegeneration and neuroinflammation⁶¹. Our previous work on the
310 same data focusing on JHU region-of-interest (ROI) analysis demonstrated that MK was significantly lower in EP and
311 chronic SZ as compared to age-range matched controls⁶³. Our current analyses on the average WM skeleton and voxel-
312 wise on the skeleton revealed that lower MK was associated with higher blood GR activity in HC, but not in PT. This
313 suggests that high GR activity was linked with changes in myelin and tissue heterogeneity in HC. As high GR activity
314 may be sign of reductive stress, we looked at the relationship between GR and MK in individuals with low GPx/GR-
315 ratio. This revealed that the difference in the GR-MK association between PT and HC were indeed mostly driven by
316 individuals displaying a low GPx/GR-ratio. This suggests that reductive stress in blood is linked to a low MK in WM
317 of HC, while this does not appear to be the sole modulator of MK in PT. Here, the lack of a direct association between
318 MK and GR in PT could suggest there are multiple mechanisms affecting WM integrity in PT, and thus a less direct
319 relationship than in HC.

320 Prior research has shown that NAC treatment can improve brain GSH levels after six months⁴⁹ and WM integrity as
321 measured by gFA in PT⁴⁸. Notably, improvements in cognitive abilities and in symptoms⁴⁹, particularly in individuals
322 with high GPx levels, have also been reported, highlighting the interplay between blood markers, WM integrity and
323 cognitive function. However, we found no associations between GPx or high-ratio GPx with WM microstructure in PT,
324 contrary to our expectation, further substantiating the possibility that multiple mechanisms are influencing the WM
325 integrity in PT.

326 As a side note, while we found group differences in WM microstructure metrics at the JHU ROI level and their
327 ensemble in our prior research⁶³, here we did not find group differences in the WM skeleton as defined by TBSS
328 analysis. This suggests that considering larger or specific ROIs may be more important for detecting group differences
329 than just the WM skeleton. However, the previously described MK-GR relationship remains unaffected by the mask
330 used, showing consistent results for both the JHU ensemble and WM skeleton (not shown). Interestingly, the spatial
331 localization of the strongest GR-MK significant contrasts between HC and PT (**Fig. 2D**) coincides with the FA WM
332 ROIs (CR, genu and body of the CC) showing the strongest effect size between HC and PT found in the large meta-
333 analysis of the ENIGMA study group⁴⁶ and similarly reported in our previous study⁶³.

335 *Limitations*

336
337 Our study has a few limitations that need to be considered. First, we used harmonization procedures to remove both
338 the effects of MRI scanner and of plate readers used to quantify the redox markers. In addition, the delay between
339 MRI acquisition and blood collection could be another source of bias⁸ despite being capped and controlled during the
340 statistical analyses. The small sample size and heterogeneity among the PT cohort (that includes early psychosis PT
341 and subjects with chronic SZ) may significantly reduce the statistical power due to potential conflicting trends that
342 may arise at WM microstructure or GSH-system levels across the different stages and types of psychosis. Finally, GPx
343 and GR activities and their ratio in blood cells inform us about the systemic redox homeostasis which does not
344 necessarily reflect the conditions found in the brain. However, it is likely that systemic redox dysregulation impact
345 brain structure and function. Indeed, several studies have found associations of peripheral markers of the GSH-redox

346 cycle with brain GSH levels⁹⁵, brain atrophy and enlargement of the lateral ventricles⁹⁶, or EEG sensory evoked
347 responses⁹⁷.

348
349 *Conclusions*

351 Altogether, our extensive association analyses indicate that while the peripheral GSH-redox cycle may predict WM
352 microstructural properties such as MK in HC and age-dependent increase of MD in WM, it does not alone explain the
353 WM anomalies detected in PT. Our results do not however exclude the involvement of the GSH redox cycle during the
354 development/maturation of WM. The dysregulation of this system during brain development could still contribute
355 to WM anomalies in psychosis.

358 **Acknowledgments**

359 This work was supported by the Swiss National Science Foundation (PCEFP2_194260, to I.J.; 320030_197787 to PH
360 and YA), the National Center of Competence in Research (NCCR) “SYNAPSY - The Synaptic Bases of Mental Diseases”
361 from the Swiss National Science Foundation (n° 51NF40 – 185897 to KQD & PC) and the Foundation Alamaya. Dr.
362 Alameda is supported by Carigest fellowship and by Frutiger Adrian et Simone fellowship. Dr. Dwir and P. Klauser
363 are supported by Frutiger Adrian & Simone fellowship. The authors have nothing to disclose and there are no
364 conflicts of interest. We are grateful to Gloria Reuteler, Adeline Cottier and Morgane Baumgartner for expert technical
365 assistance. Dr Luis Alameda thanks the Foundation Adrian and Simone Frutiger and Carigest SA Foundation for their
366 support

368 **References**

- 369 1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental
370 disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol J Eur Coll*
371 *Neuropsychopharmacol*. 2011;21(9):655-679. doi:10.1016/j.euroneuro.2011.07.018
- 372 2. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—An Overview. *JAMA Psychiatry*. 2020;77(2):201-
373 210. doi:10.1001/jamapsychiatry.2019.3360
- 374 3. Dietz AG, Goldman SA, Nedergaard M. Glial cells in schizophrenia: a unified hypothesis. *Lancet Psychiatry*.
375 2020;7(3):272-281. doi:10.1016/S2215-0366(19)30302-5
- 376 4. Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. *Pharmacol Ther*.
377 2020;205:107426. doi:10.1016/j.pharmthera.2019.107426
- 378 5. Ni P, Chung S. Mitochondrial Dysfunction in Schizophrenia. *BioEssays News Rev Mol Cell Dev Biol*.
379 2020;42(6):e1900202. doi:10.1002/bies.201900202
- 380 6. Murphy CE, Walker AK, Weickert CS. Neuroinflammation in schizophrenia: the role of nuclear factor kappa
381 B. *Transl Psychiatry*. 2021;11(1):528. doi:10.1038/s41398-021-01607-0
- 382 7. Howes OD, Onwordi EC. The synaptic hypothesis of schizophrenia version III: a master mechanism. *Mol*
383 *Psychiatry*. 2023;28(5):1843-1856. doi:10.1038/s41380-023-02043-w
- 384 8. Perkins DO, Jeffries CD, Do KQ. Potential Roles of Redox Dysregulation in the Development of Schizophrenia.
385 *Biol Psychiatry*. 2020;88(4):326-336. doi:10.1016/j.biopsych.2020.03.016

- 386 9. Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, et al. Glutathione levels and activities of
387 glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. *J*
388 *Psychopharmacol (Oxf)*. 2019;33(10):1199-1214. doi:10.1177/0269881119845820
- 389 10. Rambaud V, Marzo A, Chaumette B. Oxidative Stress and Emergence of Psychosis. *Antioxid Basel Switz*.
390 2022;11(10):1870. doi:10.3390/antiox11101870
- 391 11. Jorgensen A, Baago IB, Rygner Z, Jorgensen MB, Andersen PK, Kessing LV, et al. Association of Oxidative
392 Stress-Induced Nucleic Acid Damage With Psychiatric Disorders in Adults: A Systematic Review and Meta-analysis.
393 *JAMA Psychiatry*. 2022;79(9):920-931. doi:10.1001/jamapsychiatry.2022.2066
- 394 12. Kim SY, Cohen BM, Chen X, Lukas SE, Shinn AK, Yuksel AC, et al. Redox Dysregulation in Schizophrenia
395 Revealed by in vivo NAD⁺/NADH Measurement. *Schizophr Bull*. 2017;43(1):197-204. doi:10.1093/schbul/sbw129
- 396 13. Das TK, Javadzadeh A, Dey A, Sabesan P, Théberge J, Radua J, et al. Antioxidant defense in schizophrenia and
397 bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. *Prog Neuropsychopharmacol Biol*
398 *Psychiatry*. 2019;91:94-102. doi:10.1016/j.pnpbp.2018.08.006
- 399 14. Ma J, Li DM, Zhang R, Yang XD, Gao CG, Lu SM, et al. Genetic analysis of glutamate cysteine ligase modifier
400 (GCLM) gene and schizophrenia in Han Chinese. *Schizophr Res*. 2010;119(1-3):273-274.
401 doi:10.1016/j.schres.2009.12.017
- 402 15. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and Oxidative Stress: Glutamate
403 Cysteine Ligase Modifier as a Susceptibility Gene. *Am J Hum Genet*. 2006;79(3):586-592. doi:10.1086/507566
- 404 16. Rodríguez-Santiago B, Brunet A, Sobrino B, Serra-Juhé C, Flores R, Armengol L, et al. Association of common
405 copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia.
406 *Mol Psychiatry*. 2010;15(10):1023-1033. doi:10.1038/mp.2009.53
- 407 17. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, et al. Genetic polymorphisms of glutathione
408 S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. *Psychiatry Res*. 2011;187(3):454-
409 456. doi:10.1016/j.psychres.2010.10.008
- 410 18. Yan C, Duan L, Fu C, Tian C, Zhang B, Shao X, et al. Association Between Glutathione S-Transferase (GST)
411 Polymorphisms and Schizophrenia in a Chinese Han Population. *Neuropsychiatr Dis Treat*. 2020;16(null):479-487.
412 doi:10.2147/NDT.S235043
- 413 19. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in
414 schizophrenia: Convergent genetic and functional evidence. *Proc Natl Acad Sci*. 2007;104(42):16621-16626.
415 doi:10.1073/pnas.0706778104

- 416 20. Yao JK, Leonard S, Reddy R. Altered Glutathione Redox State in Schizophrenia. *Dis Markers*.
417 NaN/NaN/NaN;22(1-2):83-93. doi:10.1155/2006/248387
- 418 21. Gawryluk JW, Wang JF, Andreatza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain
419 antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *Int J Neuropsychopharmacol*.
420 2011;14(1):123-130. doi:10.1017/S1461145710000805
- 421 22. Zhang Y, Catts VS, Shannon Weickert C. Lower antioxidant capacity in the prefrontal cortex of individuals
422 with schizophrenia. *Aust N Z J Psychiatry*. 2018;52(7):690-698. doi:10.1177/0004867417728805
- 423 23. Flatow J, Buckley P, Miller BJ. Meta-Analysis of Oxidative Stress in Schizophrenia. *Biol Psychiatry*.
424 2013;74(6):400-409. doi:10.1016/j.biopsych.2013.03.018
- 425 24. Fournier M, Scolamiero M, Gholam-Rezaee MM, Cleusix M, Jenni R, Ferrari C, et al. Topology predicts long-
426 term functional outcome in early psychosis. *Mol Psychiatry*. 2021;26(9):5335-5346. doi:10.1038/s41380-020-0826-
427 1
- 428 25. Monin A, Fournier M, Baumann PS, Cuénod M, Do KQ. Role of Redox Dysregulation in White Matter Anomalies
429 Associated with Schizophrenia. In: *Handbook of Behavioral Neuroscience*. Vol 23. Elsevier; 2016:481-500.
430 doi:10.1016/B978-0-12-800981-9.00028-6
- 431 26. Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M, et al. Glutathione deficit impairs myelin
432 maturation: relevance for white matter integrity in schizophrenia patients. *Mol Psychiatry*. 2015;20(7):827-838.
433 doi:10.1038/mp.2014.88
- 434 27. Juurlink BH, Thorburne SK, Hertz L. Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to
435 oxidative stress. *Glia*. 1998;22(4):371-378. doi:10.1002/(sici)1098-1136(199804)22:4<371::aid-glia6>3.0.co;2-6
- 436 28. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. *Acta Neuropathol (Berl)*. 2010;119(1):37-
437 53. doi:10.1007/s00401-009-0601-5
- 438 29. Thorburne SK, Juurlink BH. Low glutathione and high iron govern the susceptibility of oligodendroglial
439 precursors to oxidative stress. *J Neurochem*. 1996;67(3):1014-1022. doi:10.1046/j.1471-4159.1996.67031014.x
- 440 30. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ. Maturation-Dependent Vulnerability of Oligodendrocytes to
441 Oxidative Stress-Induced Death Caused by Glutathione Depletion. *J Neurosci*. 1998;18(16):6241-6253.
442 doi:10.1523/JNEUROSCI.18-16-06241.1998
- 443 31. Ravera S, Bartolucci M, Cuccarolo P, Litamè E, Illarcio M, Calzia D, et al. Oxidative stress in myelin sheath: The
444 other face of the extramitochondrial oxidative phosphorylation ability. *Free Radic Res*. 2015;49(9):1156-1164.
445 doi:10.3109/10715762.2015.1050962

- 446 32. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA. Glutathione peroxidase-catalase cooperativity is
447 required for resistance to hydrogen peroxide by mature rat oligodendrocytes. *J Neurosci Off J Soc Neurosci.*
448 2004;24(7):1531-1540. doi:10.1523/JNEUROSCI.3989-03.2004
- 449 33. Nave KA, Asadollahi E, Sasmita A. Expanding the function of oligodendrocytes to brain energy metabolism.
450 *Curr Opin Neurobiol.* 2023;83:102782. doi:10.1016/j.conb.2023.102782
- 451 34. Smith GA, Lin TH, Sheehan AE, Van der Goes van Naters W, Neukomm LJ, Graves HK, et al. Glutathione S-
452 Transferase Regulates Mitochondrial Populations in Axons through Increased Glutathione Oxidation. *Neuron.*
453 2019;103(1):52-65.e6. doi:10.1016/j.neuron.2019.04.017
- 454 35. Dwir D, Giangreco B, Xin L, Tenenbaum L, Cabungcal JH, Steullet P, et al. MMP9/RAGE pathway overactivation
455 mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse
456 translation study in schizophrenia patients. *Mol Psychiatry.* 2020;25(11):2889-2904. doi:10.1038/s41380-019-
457 0393-5
- 458 36. Lloyd AF, Davies CL, Miron VE. Microglia: origins, homeostasis, and roles in myelin repair. *Curr Opin*
459 *Neurobiol.* 2017;47:113-120. doi:10.1016/j.conb.2017.10.001
- 460 37. Uranova NA, Vikhрева OV, Rachmanova VI, Orlovskaya DD. Ultrastructural Alterations of Myelinated Fibers
461 and Oligodendrocytes in the Prefrontal Cortex in Schizophrenia: A Postmortem Morphometric Study. *Schizophr Res*
462 *Treat.* 2011;2011:e325789. doi:10.1155/2011/325789
- 463 38. Uranova NA, Vikhрева OV, Rakhmanova VI, Orlovskaya DD. Ultrastructural pathology of oligodendrocytes
464 adjacent to microglia in prefrontal white matter in schizophrenia. *Npj Schizophr.* 2018;4(1):1-10.
465 doi:10.1038/s41537-018-0068-2
- 466 39. Williams M, ed. *The Neuropathology of Schizophrenia*. Cham: Springer International Publishing; 2021.
467 doi:10.1007/978-3-030-68308-5
- 468 40. Uranova NA, Vikhрева OV, Rakhmanova VI, Orlovskaya DD. Dystrophy of Oligodendrocytes and Adjacent
469 Microglia in Prefrontal Gray Matter in Schizophrenia. *Front Psychiatry.* 2020;11.
470 <https://www.frontiersin.org/articles/10.3389/fpsy.2020.00204>. Accessed March 10, 2023.
- 471 41. Beaulieu C. The basis of anisotropic water diffusion in the nervous system - a technical review. *NMR Biomed.*
472 2002;15(7-8):435-455. doi:10.1002/nbm.782
- 473 42. Cetin-Karayumak S, Di Biase MA, Chunga N, Reid B, Somes N, Lyall AE, et al. White matter abnormalities
474 across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study. *Mol Psychiatry.* 2020;25(12):3208-
475 3219. doi:10.1038/s41380-019-0509-y

- 476 43. Friedman Joseph I, Tang C, Carpenter D, Buchsbaum M, Schmeidler J, Flanagan L, et al. Diffusion Tensor
477 Imaging Findings in First-Episode and Chronic Schizophrenia Patients. *Am J Psychiatry*. 2008;165(8):1024-1032.
478 doi:10.1176/appi.ajp.2008.07101640
- 479 44. Barth C, Kelly S, Nerland S, Jahanshad N, Alloza C, Ambrogio S, et al. In vivo white matter microstructure in
480 adolescents with early-onset psychosis: a multi-site mega-analysis. *Mol Psychiatry*. 2023;28(3):1159-1169.
481 doi:10.1038/s41380-022-01901-3
- 482 45. Karlsgodt KH. White Matter Microstructure across the Psychosis Spectrum. *Trends Neurosci*.
483 2020;43(6):406-416. doi:10.1016/j.tins.2020.03.014
- 484 46. Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, et al. Widespread white matter microstructural
485 differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group.
486 *Mol Psychiatry*. 2018;23(5):1261-1269. doi:10.1038/mp.2017.170
- 487 47. van Velzen LS, Kelly S, Isaev D, Aleman A, Aftanas LI, Bauer J, et al. White matter disturbances in major
488 depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group. *Mol*
489 *Psychiatry*. 2020;25(7):1511-1525. doi:10.1038/s41380-019-0477-2
- 490 48. Klauser P, Xin L, Fournier M, Griffa A, Cleusix M, Jenni R, et al. N-acetylcysteine add-on treatment leads to an
491 improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial.
492 *Transl Psychiatry*. 2018;8(1):1-8. doi:10.1038/s41398-018-0266-8
- 493 49. Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N-acetylcysteine in a Double-Blind
494 Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. *Schizophr Bull*.
495 2018;44(2):317-327. doi:10.1093/schbul/sbx093
- 496 50. Jensen JH, Helpert JA, Ramani A, Lu H, Kaczynski K. Diffusional kurtosis imaging: The quantification of non-
497 gaussian water diffusion by means of magnetic resonance imaging. *Magn Reson Med*. 2005;53(6):1432-1440.
498 doi:10.1002/mrm.20508
- 499 51. Jensen JH, Helpert JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. *NMR Biomed*.
500 2010;23(7):698-710. doi:10.1002/nbm.1518
- 501 52. Jespersen SN, Olesen JL, Hansen B, Shemesh N. Diffusion time dependence of microstructural parameters in
502 fixed spinal cord. *NeuroImage*. 2018;182:329-342. doi:10.1016/j.neuroimage.2017.08.039
- 503 53. Fieremans E, Jensen JH, Helpert JA. White matter characterization with diffusional kurtosis imaging.
504 *NeuroImage*. 2011;58(1):177-188. doi:10.1016/j.neuroimage.2011.06.006

- 505 54. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation
506 dispersion and density imaging of the human brain. *NeuroImage*. 2012;61(4):1000-1016.
507 doi:10.1016/j.neuroimage.2012.03.072
- 508 55. Novikov DS, Kiselev VG, Jespersen SN. On modeling. *Magn Reson Med*. 2018;79(6):3172-3193.
509 doi:10.1002/mrm.27101
- 510 56. Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimination and mapping from diffusion MRI.
511 *Magn Reson Med*. 2009;62(3):717-730. doi:10.1002/mrm.22055
- 512 57. Guglielmetti C, Veraart J, Roelant E, Mai Z, Daans J, Van Audekerke J, et al. Diffusion kurtosis imaging probes
513 cortical alterations and white matter pathology following cuprizone induced demyelination and spontaneous
514 remyelination. *NeuroImage*. 2016;125:363-377. doi:10.1016/j.neuroimage.2015.10.052
- 515 58. Jelescu IO, Zurek M, Winters KV, Veraart J, Rajaratnam A, Kim NS, et al. In vivo quantification of demyelination
516 and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy. *NeuroImage*.
517 2016;132:104-114. doi:10.1016/j.neuroimage.2016.02.004
- 518 59. Wang Y, Wang Q, Haldar JP, Yeh FC, Xie M, Sun P, et al. Quantification of increased cellularity during
519 inflammatory demyelination. *Brain*. 2011;134(12):3590-3601. doi:10.1093/brain/awr307
- 520 60. Falangola MF, Guilfoyle DN, Tabesh A, Hui ES, Nie X, Jensen JH, et al. Histological correlation of diffusional
521 kurtosis and white matter modeling metrics in cuprizone-induced corpus callosum demyelination. *NMR Biomed*.
522 2014;27(8):948-957. doi:10.1002/nbm.3140
- 523 61. Jelescu IO, Fieremans E. Chapter 2 - Sensitivity and specificity of diffusion MRI to neuroinflammatory
524 processes. In: Laule C, Port JD, eds. *Advances in Magnetic Resonance Technology and Applications*. Vol 9. Imaging
525 Neuroinflammation. Academic Press; 2023:31-50. doi:10.1016/B978-0-323-91771-1.00010-1
- 526 62. Wijtenburg SA, Rowland LM. Chapter 19 - Schizophrenia spectrum disorders. In: Laule C, Port JD, eds.
527 *Advances in Magnetic Resonance Technology and Applications*. Vol 9. Imaging Neuroinflammation. Academic Press;
528 2023:469-487. doi:10.1016/B978-0-323-91771-1.00008-3
- 529 63. Pavan T, Alemán-Gómez Y, Jenni R, Steullet P, Schilliger Z, Dwir D, et al. White Matter Microstructure
530 Alterations in Early Psychosis and Schizophrenia. April 2024:2024.02.01.24301979.
531 doi:10.1101/2024.02.01.24301979
- 532 64. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the
533 Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry*. 2005;39(11-12):964-971.
534 doi:10.1080/j.1440-1614.2005.01714.x

- 535 65. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. *Schizophr*
536 *Bull.* 1987;13(2):261-276. doi:10.1093/schbul/13.2.261
- 537 66. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (4th Ed., Text Rev.)*;
538 2000.
- 539 67. Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction.
540 *IEEE Trans Med Imaging.* 2010;29(6):1310-1320. doi:10.1109/TMI.2010.2046908
- 541 68. Grabner G, Janke AL, Budge MM, Smith D, Pruessner J, Collins DL. Symmetric Atlasing and Model Based
542 Segmentation: An Application to the Hippocampus in Older Adults. In: Larsen R, Nielsen M, Sporring J, eds. *Medical*
543 *Image Computing and Computer-Assisted Intervention – MICCAI 2006*. Lecture Notes in Computer Science. Berlin,
544 Heidelberg: Springer; 2006:58-66. doi:10.1007/11866763_8
- 545 69. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-
546 correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med Image Anal.* 2008;12(1):26-
547 41. doi:10.1016/j.media.2007.06.004
- 548 70. Ades-Aron B, Veraart J, Kochunov P, McGuire S, Sherman P, Kellner E, et al. Evaluation of the accuracy and
549 precision of the diffusion parameter Estimation with Gibbs and Noise removal pipeline. *NeuroImage.* 2018;183:532-
550 543. doi:10.1016/j.neuroimage.2018.07.066
- 551 71. Veraart J, Sijbers J, Sunaert S, Leemans A, Jeurissen B. Weighted linear least squares estimation of diffusion
552 MRI parameters: Strengths, limitations, and pitfalls. *NeuroImage.* 2013;81:335-346.
553 doi:10.1016/j.neuroimage.2013.05.028
- 554 72. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes
555 methods. *Biostat Oxf Engl.* 2007;8(1):118-127. doi:10.1093/biostatistics/kxj037
- 556 73. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for
557 Statistical Computing; 2023. <https://www.R-project.org/>.
- 558 74. Maechler M, Rousseeuw P, Croux C, Todorov V, Ruckstuhl A, Salibian-Barrera M, et al. *Robustbase: Basic*
559 *Robust Statistics*; 2023. <http://robustbase.r-forge.r-project.org/>.
- 560 75. Martínez De Toda I, Vida C, Garrido A, De La Fuente M. Redox Parameters as Markers of the Rate of Aging and
561 Predictors of Life Span. *J Gerontol Ser A.* February 2019. doi:10.1093/gerona/glz033
- 562 76. Jones DP, Mody VC, Carlson JL, Lynn MJ, Sternberg P. Redox analysis of human plasma allows separation of
563 pro-oxidant events of aging from decline in antioxidant defenses. *Free Radic Biol Med.* 2002;33(9):1290-1300.
564 doi:10.1016/S0891-5849(02)01040-7

- 565 77. Fortin JP, Parker D, Tunç B, Watanabe T, Elliott MA, Ruparel K, et al. Harmonization of multi-site diffusion
566 tensor imaging data. *NeuroImage*. 2017;161:149-170. doi:10.1016/j.neuroimage.2017.08.047
- 567 78. Alemán-Gómez Y, Najdenovska E, Roine T, Fartaria MJ, Canales-Rodríguez EJ, Rovó Z, et al. Partial-volume
568 modeling reveals reduced gray matter in specific thalamic nuclei early in the time course of psychosis and chronic
569 schizophrenia. *Hum Brain Mapp*. 2020;41(14):4041-4061. doi:10.1002/hbm.25108
- 570 79. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial
571 statistics: voxelwise analysis of multi-subject diffusion data. *NeuroImage*. 2006;31(4):1487-1505.
572 doi:10.1016/j.neuroimage.2006.02.024
- 573 80. Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear
574 model. *NeuroImage*. 2014;92:381-397. doi:10.1016/j.neuroimage.2014.01.060
- 575 81. Koga M, Serritella AV, Sawa A, Sedlak TW. Implications for reactive oxygen species in schizophrenia
576 pathogenesis. *Schizophr Res*. 2016;176(1):52-71. doi:10.1016/j.schres.2015.06.022
- 577 82. Martínez de Toda I, Vida C, Sanz San Miguel L, De la Fuente M. Function, Oxidative, and Inflammatory Stress
578 Parameters in Immune Cells as Predictive Markers of Lifespan throughout Aging. *Oxid Med Cell Longev*.
579 2019;2019:4574276. doi:10.1155/2019/4574276
- 580 83. Stadtman ER. Importance of individuality in oxidative stress and aging. *Free Radic Biol Med*. 2002;33(5):597-
581 604. doi:10.1016/s0891-5849(02)00904-8
- 582 84. Schilliger Z, Alemán-Gómez Y, Magnus Smith M, Celen Z, Meuleman B, Binz PA, et al. Sex-specific interactions
583 between stress axis and redox balance are associated with internalizing symptoms and brain white matter
584 microstructure in adolescents. *Transl Psychiatry*. 2024;14(1):1-11. doi:10.1038/s41398-023-02728-4
- 585 85. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant
586 enzyme activities in untreated and treated schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry*.
587 2009;33(7):1178-1183. doi:10.1016/j.pnpbp.2009.06.018
- 588 86. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. Activities of superoxide dismutase and glutathione
589 peroxidase in schizophrenic and manic-depressive patients. *Clin Chem*. 1986;32(5):805-807.
590 doi:10.1093/clinchem/32.5.805
- 591 87. Martínez de Toda I, González-Sánchez M, Díaz-Del Cerro E, Valera G, Carracedo J, Guerra-Pérez N. Sex
592 differences in markers of oxidation and inflammation. Implications for ageing. *Mech Ageing Dev*. 2023;211:111797.
593 doi:10.1016/j.mad.2023.111797

- 594 88. Dukhande VV, Isaac AO, Chatterji T, Lai JCK. Reduced glutathione regenerating enzymes undergo
595 developmental decline and sexual dimorphism in the rat cerebral cortex. *Brain Res.* 2009;1286:19-24.
596 doi:10.1016/j.brainres.2009.05.029
- 597 89. Ruszkiewicz JA, Miranda-Vizuete A, Tinkov AA, Skalnaya MG, Skalny AV, Tsatsakis A, et al. Sex-Specific
598 Differences in Redox Homeostasis in Brain Norm and Disease. *J Mol Neurosci.* 2019;67(2):312-342.
599 doi:10.1007/s12031-018-1241-9
- 600 90. Alameda L, Fournier M, Khadimallah I, Griffa A, Cleusix M, Jenni R, et al. Redox dysregulation as a link
601 between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis. *Proc*
602 *Natl Acad Sci U S A.* 2018;115(49):12495-12500. doi:10.1073/pnas.1812821115
- 603 91. Korge P, Calmettes G, Weiss JN. Increased reactive oxygen species production during reductive stress: The
604 roles of mitochondrial glutathione and thioredoxin reductases. *Biochim Biophys Acta BBA - Bioenerg.*
605 2015;1847(6):514-525. doi:10.1016/j.bbabi.2015.02.012
- 606 92. Bouhrara M, Avram AV, Kiely M, Trivedi A, Benjamini D. Adult lifespan maturation and degeneration patterns
607 in gray and white matter: A mean apparent propagator (MAP) MRI study. *Neurobiol Aging.* 2023;124:104-116.
608 doi:10.1016/j.neurobiolaging.2022.12.016
- 609 93. Teissier T, Boulanger E, Deramecourt V. Normal ageing of the brain: Histological and biological aspects. *Rev*
610 *Neurol (Paris).* 2020;176(9):649-660. doi:10.1016/j.neurol.2020.03.017
- 611 94. Okusaga OO. Accelerated Aging in Schizophrenia Patients: The Potential Role of Oxidative Stress. *Aging Dis.*
612 2013;5(4):256-262. doi:10.14336/AD.2014.0500256
- 613 95. Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic Polymorphism Associated
614 Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis.
615 *Schizophr Bull.* 2016;42(5):1185-1196. doi:10.1093/schbul/sbw038
- 616 96. Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan
617 abnormalities in schizophrenia. *Biol Psychiatry.* 1987;22(11):1349-1356. doi:10.1016/0006-3223(87)90069-2
- 618 97. Geiser E, Retsa C, Knebel JF, Ferrari C, Jenni R, Fournier M, et al. The coupling of low-level auditory
619 dysfunction and oxidative stress in psychosis patients. *Schizophr Res.* 2017;190:52-59.
620 doi:10.1016/j.schres.2017.02.002

621

622


623 **Figures and Tables**

624

	HC (N=86)		PT (N=99)		Stat.	p-value	
	Mean	Std.	Men	Std.			
Age (years)	28.1	8.6	29.0	9.4	W=3989	p=4.6e-01ns	
GPx	16.7	6.6	16.2	6.1			
GR	2.5	0.7	2.3	0.7			
GPx/GR-ratio	6.9	2.7	7.3	3.2			
Delay MRI-Biomarker (days) [†]	17.9	31.7	39.2 [†]	44.0 [†]	W=2444	p=8.9e-07****	
Age at Psychosis Onset (years)			23.3	7.3			
Duration of illness (months)			61.9	85.2			
CPZ-equivalent dose (mg/day)			342.1	276.8			
PANSS: total			62.4	15.2			
PANSS: positive symptoms			13.2	4.3			
PANSS: negative symptoms			16.8	5.8			
PANSS: general psychopathology			32.6	8.2			
GAF	84.9	4.1	55.7	11.6	W=7962	p=1.8e-30****	
	N	Pct.	N	Pct.			
Scanner	Prisma	68	79.1	74	74.7	χ^2 :0.482	p=0.488
	Trio	18	20.9	25	25.5		
Sex	Female	32	37.2	24	24.2	χ^2 :3.66	p=0.056
	Male	54	62.8	75	75.8		
Reader	Infinite	66	76.7	87	87.9	χ^2 :3.98	p=0.046*
	SPARK	20	23.3	12	12.1		
GPx/GR-Ratio	High	44	51.2	48	48.5		
	Low	42	48.8	51	51.5		


625 **Table 1** Cohort demographics. P-values refer to Wilcox's tests between patients and healthy control. χ^2 test is computed for the
626 scanner, sex, and reader contingency tables. GPx and GR activities are expressed in nmoles NADPH used/min/g hemoglobin. HC:
627 healthy controls, PT: patients, GPx: glutathione peroxidase, GR: glutathione reductase, GAF: Global Assessment of Functioning,
628 PANSS: Positive and Negative Syndrome Scale. †: the delay MRI-biomarker statistics are reported excluding one PT participant
629 with an extreme delay of 271 days.

630



631 **Figure 1 Biomarkers of the blood GSH-redox cycle and the effects of sex and clinical status.** Correlations
632 between GPx and GR activity in the whole cohort, colored by the quartiles of the ratio between GPx and GR (A), clinical
633 status (B), and sex (C). GPx and GR activities are expressed in nmoles NADPH used/min/g hemoglobin. GPx: GSH
634 peroxidase; GR: GSH reductase; HC: healthy controls; PT: patients; M: males; F: females.


635



636 **Figure 2 Significant associations found between biomarkers of the blood GSH-redox cycle and the dMRI**
 637 **microstructure estimates.** Scatter plots A and B show the associations between GR activity and MK (A) and f (B)
 638 mean WM skeleton of HC (blue) vs patients (orange). Plot C shows the association of GPx/GR-ratio and f WM skeleton.
 639 GR activity is expressed in nmoles NADPH used/min/g hemoglobin. Brain plots D and E show the results for the TBSS
 640 analysis for the regressions of plot A ($p_{FDR} \leq 0.05$). GR was found significantly associated with MK in HC (E) and differed
 641 from the PT slope (D). Clusters were identified in the bilateral superior corona radiata, genu and body of the corpus
 642 callosum. Results are corrected for age², sex, and delay. GR: glutathione reductase; MK: mean kurtosis; f : axonal water
 643 fraction; β_{HC} : slope of HC; β_{PT} : slope of the PT.

644


645



646 **Figure 3 Associations between MD and Ageing are modulated by GPx independently of the clinical status.** The
647 regression lines represent the robust fitting of the association between MD and (quadratic) age-GPx interaction, when
648 GPx is fixed at its 2nd (blue curve) and 4th quartiles (red curve). PT and HC are plotted together. At lower GPx (blue
649 curve), MD increases faster after 40 years of age than in subjects with high GPx, possibly indicating worse aging. At a
650 younger age the difference is not detectable. GPx and GR activities are expressed in nmoles NADPH used/min/g
651 hemoglobin.

652

653



654 **Figure 4 Associations between GR and mean kurtosis estimates among individuals with low GPx/GR-ratio.**
655 The scatterplots show the GPx (A) and GR (B) association with the MK mean-WM skeletons of individuals with low
656 GPx/GR-ratio. GR activity is expressed in nmoles NADPH used/min/g hemoglobin. Plot (C) shows the TBSS analysis
657 results of the same associations. In red/yellow are plotted the significant voxels ($p_{FDR} \leq 0.05$) of the contrast between
658 the slopes of HC and PT. Both analyses included a correction for quadratic age, sex and delay. GPx and GR activities
659 are expressed in nmoles NADPH used/min/g hemoglobin. Green: WM skeleton; HC: healthy controls; PT: patients;
660 GR: glutathione reductase; GPx: GSH peroxidase; MK: mean kurtosis; β_{HC} : slope of HC; β_{PT} : slope of the PT; Low:
661 participants with GPx/GR-ratio < median ratio of the HC group.
662